Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

Prior treatment

• Patients receiving anticoagulants for other comorbidities
• Planned surgery or intervention which needs to stop antiplatelet agents ≥1 month

Other illness

• A history of a diagnosed cardiovascular or cerebrovascular disease (Type1 myocardial infarction, heart failure, peripheral artery disease, stroke, transient ischemic attack, carotid artery stenosis\>50%, carotid artery intervention)
• A history of coronary artery intervention or coronary artery bypass graft surgery, which needs chronic maintenance of antiplatelet therapy
• Absolute contraindication or allergy to clopidogrel
• A history of Bleeding diathesis, known coagulopathy, or major bleeding, BARC class ≥3, resulting in the stop of antiplatelet agents

Age

• Presence of non-cardiac comorbidity with life expectancy ≤ 5 years at randomization

Other

• Females with pregnancy or breast-feeding
• Patients who are thought to be inappropriate for the trial based on physicians' decision

• Male or female aged ≥40 years
• Patients with subclinical coronary atherosclerosis identified from coronary CT angiography or coronary angiography within 2 years without clinical events after an imaging study
• Without significant coronary artery stenosis (Diameter stenosis \>50%), which needs revascularization
• Agreement to give written informed consent